[8] Mok T, Peters S, Camidge DR. Patients with ALK IHC-positive/fish-negative NSCLC benefit from ALK TKI treatment: response data from the global ALEX trial. Presented at: the IASLC 18th World Conference on Lung Cancer; October 15-18; Yokohama, Japan. Poster MA 07.01.

[9] CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib. Cancer Biol Ther. 2018 Oct 1:1-5.

[10] Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. The Oncologist. 2016;21(6):762-770.

[11] www.nccn.org/patients.

[12] Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. J Clin Oncol 2018, 36:911-919.

• 养生|钟南山的养生经：健康长寿的秘诀，其实就简单3点，分享给你
• 李湘减肥成功了？大方分享“减肥秘籍”，方法或值得学习
• 好物分享丨减肥还管不住嘴？减脂零食快看一看，嘴馋星人必备
• 今日份的冷知识也是很有趣，这不得分享一波？
• 98岁肝胆科之父：研究乙肝60载，分享3条“实战方”
• 尿酸高，如何让尿酸排出体外？医生分享3个办法，或许值得一试
• 腹痛患者偶然诊断十二指肠贾第虫病｜病例分享
• 个人经验：我如何找到完美的睡眠模式并优化我的生活
• 还在凭经验？科室主任和护士长要这样当
• 多案例分享：如何规范撰写统计分析方法